{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-120864","form_type":"8-K","ticker":"BIOA","cik":"0001709941","company_name":"BioAge Labs, Inc.","filed_at":"2026-03-24T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.966111+00:00","generated_at":"2026-05-15T09:13:53.260826+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"BioAge reports FY2025 net loss $80.6M; positive BGE-102 Phase 1 data; $132M offering","bullets":["Positive interim Phase 1 data for BGE-102: 86% median hsCRP reduction, 93% of obese participants reached <2 mg/L.","Phase 2a cardiovascular trial planned 1H 2026; ophthalmology expansion with DME trial mid-2026.","Completed $132.3M follow-on offering in Feb 2026; cash $285.1M at Dec 31, 2025, sufficient through 2029.","FY2025: collaboration revenue $9.0M (vs $0); net loss $80.6M ($2.24/share) vs $71.1M ($6.63/share) in 2024.","APJ agonist programs advancing; IND filing expected by end of 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-120864","json":"https://secwatch.observer/filing/0001193125-26-120864.json","markdown":"https://secwatch.observer/filing/0001193125-26-120864.md","text":"https://secwatch.observer/filing/0001193125-26-120864.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1709941/000119312526120864/0001193125-26-120864-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1709941/000119312526120864/bioa-20260324.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T09:13:53.260826+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}